A Robust and Scalable Process for the Synthesis of Substantially Pure Clarithromycin 9-()-Oxime with an Established Control of the ()-Isomer Impurity.

Controlling the isomeric impurity in a key raw material is always critical to achieve the corresponding pure isomer-free targeted active pharmaceutical ingredient (API) in downstream processing. Clarithromycin 9-()-oxime is the key raw material for the synthesis of the 9a-lactam macrolide, which is an interesting scaffold for the synthesis of several bioactive macrolides. Here demonstrated is a scalable process for the preparation of substantially pure clarithromycin 9-()-oxime, with less than 1.2% of the ()-isomer. The process does not involve a separate time-consuming purification by a crystallization operation to purge the undesired ()-oxime isomer. Further, the pure clarithromycin 9-()-oxime obtained was subjected to the Beckmann rearrangement, thereby converting it into the pure 9a-lactam scaffold. Additionally, a few other impurities were identified and controlled at each stage. The fine-tuned process was successfully up scaled to a multikilogram scale, enabling the large-scale manufacturing of potential APIs derived from this scaffold.